Jazz Pharmaceuticals sold a preferred review warrant (PRV) for $200 million. The company announced this during a presentation at the J.P. conference on Tuesday. Morgan Healthcare Conference in 2026. The sale price reflects the recent change in the market value of such vouchers. Jazz plans more PRV deals in 2026. This sale shows increasing PRV prices in a market that is not stopping.[1]